Andrew is a member of the Institute of Inflammation and Ageing and an integral part of the NIHR Birmingham Biomedical Research Centre. He is a passionate advocate for translational medicine – helping to make connections between the laboratory and patients.
He brings skills in musculoskeletal ultrasound and the novel ultrasound guided synovial biopsy technique to bear upon the Birmingham BEACON early arthritis research cohort and interventional clinical trials in arthritis.
With Dr Karim Raza he has run the Birmingham Early Arthritis Clinic for five years, working on novel clinical, serological, and imaging predictors of outcome in the very early window of arthritis. He is an experienced musculoskeletal sonographer and is investigating the role of musculoskeletal ultrasound as a predictive tool in early arthritis.
Andrew’s current research is focused on 3 main areas:
Investigating pathways of persistence of disease and resolution of inflammation in early arthritis: This work uses stromal cell resources and tissue from patients in the early stages of arthritis and seeks to understand fully the contribution of these cells to inflammation and damage in arthritis. The research also explores the change in cellular phenotype during the early development and progression of rheumatoid arthritis.
Translation and intervention: this work includes development of mesenchymal stromal cellular therapies in arthritis and repurposing of therapies targeting stromal cells in cancer for use in rheumatoid arthritis.
Imaging: the use and development of novel imaging modalities including musculoskeletal ultrasound in clinical research.